Tag Archives: LSN

Hot Investor Mandate 1: Corporate Venture Arm Invests in Repurposed Drugs and New Combinations in CNS & Respiratory Disease Indications

7 Jun

A venture capital arm of a global pharmaceutical based in India was established to invest in early stage ideas with breakthrough technologies addressing major unmet medical needs. The firm also has an in-licensing arm and a specialty products incubator. The firm seeks to make equity investments in Seed and Series A/B rounds with an ultimate possibility of acquisition. The firm has a global mandate and is currently seeking new investment opportunities.

The firm is currently seeking to invest in early to mid-stage repurposed drugs, repositioned drugs, combination therapies, and new delivery technologies and devices for old drugs. In terms of indications, the firm is focused on CNS and respiratory diseases. The firm will prioritize 505(b)(2) opportunities.

The firm seeks companies with a strong and experienced management team. The firm may take a board seat/board observer rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , ,

Hot Investor Mandate 2: Taiwan Cross Border VC Seeks Medical Devices, Diagnostic Tools, Digital Health, Healthcare IoT Technologies

7 Jun

An early-stage venture capital firm based in Taipei, Taiwan is actively investing in the life sciences space. Formed by a group of successful entrepreneurs, the firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its $35 million fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm generally leads a financing round but is also open to syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , ,

Hot Investor Mandate 3: Joint Initiative Launched by a Leading Pharma and VC Firm Invests in Digital Health Companies with USA Focus

7 Jun

A digital health investment company launched in 2016 by a leading pharma and venture capital firm in the industry focuses on the digital health space ranging from therapeutics to diagnostic solutions in areas such as: precision medicine, behavioral health, wearables, and data analytics. The firm is seeking to make 6-8 new investments within the next two years. The firm’s investments range dependent on the opportunity, and focuses on investing in Seed to Series A rounds. For earlier stage companies, the firm has the ability to both lead and co-invest. The firm focuses on companies based in the U.S., but is open to invest globally.

The firm focuses on digital health technologies and solutions that aim to improve patient care and lifestyle. The firm is especially interested in technology with a software component, such as those that control patient care through monitoring medications and therapies, as well as technology with a big data component. The firm will only look at devices if they have an information component and/or generate data. The firm is also interested in technology with machine-learning applications. The firm is not interested in pure EMR or hospital IT systems. Based on all the criteria, the firm is indication agnostic.

The firm is a very active investor that seeks to be fully involved in their portfolio companies. The firm will take a board seat after the investment and will help companies fill management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , ,

Hot Investor Mandate 4: Germany-Based CVC with a Global Presence Invests in Innovative Medical Technologies Globally, Including Imaging & PoC and In Vitro Diagnostics

7 Jun

A corporate venture firm is headquartered in Munich, Germany, with additional offices worldwide. The fund invests in medical technology companies that are strategically relevant to the corporate’s interests. Investments in equity rounds range from $1-5 million and are made worldwide.

The firm’s primary focuses within healthcare are medical imaging (including both equipment and software) and diagnostics (particularly point of care diagnostics and molecular diagnostics). In these sectors, the firm focuses on products used in a hospital setting. The firm also invests in digital health solutions that add value to imaging and diagnostics, such as data-as-a-service products. The firm is potentially interested in medical robotics. The firm will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The firm generally does not attach strategic rights to an investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , ,

Life Science Nation Launches RESI Healthtech Week, Sept. 5-7, 2018

31 May

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series & RESI Healthtech Week

The inaugural RESI Healthtech Week (RESI HW) launches on September 5th at the Boston Marriott Copley Place with a new conference – the First Coast Innovator’s Gathering, where incubators, accelerators, tech transfer, university translation initiatives, hospitals, research labs and their constituents from DC, MD, PA, NJ, NY, RI, CT and MA (the first coast) will gather for the first time in one location to get on the radar screens of potential global partners. The First Coast Innovator’s Gathering is followed by the RESI Global Partnering Conference, September 6th, and the Entrepreneur’s Academy Workshop Series, September 7th.

LSN’s established network of early-stage global investors attend RESI Conference Series to source, engage and allocate funds to startup firms across the silos of biotech, medtech, diagnostics, and digital health. In addition, we present the RESI Healthtech Week!

“The First Coast is blessed with an amazing amount of technological assets addressing unmet medical needs across the entire healthcare spectrum. They need to get in front of global investors,” says Dennis Ford, CEO at Life Science Nation. This includes over 100 incubators, accelerators, tech transfer, university translation initiatives, hospitals, and research labs each with aggregate portfolios of 1000 or more assets.

Chuck Stetson, CEO of Stetson Family Office, is a Title Sponsor of the First Coast Innovator’s Investor Gathering on September 5th, and the RESI Global Investor Conference on September 6th. Stetson is pioneering a new, nonprofit, evergreen, endowment model for early-stage global companies within technology-rich innovation hubs. “It is time to address the developmental ‘valley of death’ and muster state-of-the-art resources to bring breakthrough technologies to market faster,” Stetson stated.

LSN invites the technology hubs, and their scientist/entrepreneurs, of the First Coast to take advantage of this inaugural launch. LSN created an affordable registration price that will facilitate more startups attending the three-day event. “We had to get the price point right as the early stage folks have been priced out of most of the other conferences,” said Ford. Register for the event at www.resihealthtechweek.com/.

Qualifying First Coast day 1 registrants are the northeast corridor incubators, accelerators, tech transfer, university translation initiatives, hospitals, research labs and their constituents as well as the investors and partners that seek them. Day 2 and 3 are open to all global attendees – scientist-entrepreneurs, fundraising CEOs, investors, channel partners and service providers.

Tags: , ,

Hot Investor Mandate 1: West Coast-Based Family Office Invests Up to $10M Into Early-Stage Therapeutics, Devices, and Tools Companies

31 May

A family office based in the West Coast invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies with a typical investment size of $2-10M per company. The firm will generally lead investments and invests globally with no geographic preference.

The firm is agnostic across life science sectors, including therapeutics, devices, and tools, but will not consider Healthcare IT or digital health technologies. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 2: USA Venture Fund Invests in Therapeutics and Digital Health, With Strong Interests in Small Molecule Therapies in Inflammation, Infectious, Autoimmune Diseases

31 May

A USA-based venture capital fund is currently making investments out of a $150-million-dollar fund. The firm is looking to make 15 additional investments with allocations generally in the $1-3 million range. The firm is looking to make equity investments and is open to investing in companies globally.

The firm is interested in therapeutic companies developing small molecules for inflammation, infectious and autoimmune disease and stays away from biologics, cell and gene therapy. The firm is also interested in digital health and mobile health services, AI in healthcare, B2B2C medical devices. The firm is looking for companies with some level of proof-of-concept data either in vivo or in vitro up until Phase II of clinical trials. As for digital health, the firm is looking for scalable SAAS models, novel types of healthcare delivery, point-of-care diagnostics and patient’s self-management tools.

The firm is willing to work with incomplete management teams, often working with IP that has just recently spun out of a university. The firm is willing and able to act as a lead or co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , , , , ,

← Older Entries
Newer Entries →